|
|
Volumn 10, Issue 5, 2011, Pages 329-
|
|
Deal watch: Intra-cellular therapies and Takeda to develop PDE1 inhibitors for schizophrenia
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
2 [4 [1 METHYL 4 (4 PYRIDINYL) 3 PYRAZOLYL]PHENOXYMETHYL]QUINOLINE;
DOPAMINE 2 RECEPTOR;
PHOSPHODIESTERASE 1 INHIBITOR;
PHOSPHODIESTERASE INHIBITOR;
UNCLASSIFIED DRUG;
ALZHEIMER DISEASE;
DRUG DISTRIBUTION;
DRUG INDUSTRY;
DRUG INHIBITION;
DRUG MANUFACTURE;
DRUG MARKETING;
DRUG RESEARCH;
HUMAN;
INTRACELLULAR SIGNALING;
PARKINSON DISEASE;
PRIORITY JOURNAL;
SCHIZOPHRENIA;
SHORT SURVEY;
COGNITION DISORDERS;
CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 1;
DRUG DESIGN;
DRUG INDUSTRY;
HUMANS;
PHOSPHODIESTERASE INHIBITORS;
SCHIZOPHRENIA;
|
|
EID: 79955635899
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd3438 Document Type: Short Survey |
|
Times cited : (13)
|
|
References (0)
|